Previous 10 | Next 10 |
LATAM Airlines Group (NYSE: LTM ) -41% after filing for bankruptcy . More news on: LATAM Airlines Group S.A., BioLineRx Ltd., GigaMedia Limited, Stocks on the move, , Read more ...
Gainers: Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +92% . More news on: Navidea Biopharmaceuticals, Inc., XpresSpa Group, Inc., Celsion Corporation, Stocks on the move, , Read more ...
Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +161% on positive Tc99m tilmanocept data in rheumatoid arthritis. More news on: Navidea Biopharmaceuticals, Inc., Medigus Ltd., Digirad Corporation, Stocks on the move, , Read more ...
Thinly traded nano cap Navidea Biopharmaceuticals (NYSEMKT: NAVB ) is up 89% premarket on increased volume on the heels of positive preliminary results from its ongoing Phase 2b clinical trial evaluating imaging agent Tc99m tilmanocept as an early indicator of treatment effic...
Penny Stocks To Watch Before The End Of The Month There are now 5 trading sessions left before the end of May 2020. Penny stocks have been on fire once again. This trend continues a near 2-quarter long emphasis on micro-cap stocks under $5. As happy as we all are, let’s not get too ov...
Conference Call to be held Thursday, May 21, 2020 at 5:30 pm EDT Data Support Hypothesis that Tc99m Tilmanocept Imaging Can Provide Early Indicator of Treatment Response Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”...
Navidea Biopharmaceuticals, Inc. (NAVB) Q1 2020 Results Earnings Conference Call May 14, 2020, 5:00 pm ET Company Participants Jed Latkin - Chief Executive Officer, Chief Financial Officer, Chief Operating Officer Mike Rosol - Chief Medical Officer Erika Eves - Director of Financ...
Conference Call to be held Thursday, May 14, 2020 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today ann...
Navidea Biopharmaceuticals ( NAVB +3.0% ) announces that, by mutual agreement, it has regained European commercialization and distribution rights to Lymphoseek (technetium Tc99m tilmanocept) injection from Norgine B.V. The companies inked their agreement in March 2015. More news on: Na...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and dis...
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focuse...
The Company announced today that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff’s previously announced determination to initiate delisting proceedings with respect to the Company’s com...